TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Stock Short Interest Declines 47.7%

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 9,356 shares, a decline of 47.7% from the September 15th total of 17,898 shares. Based on an average trading volume of 2,596 shares, the short-interest ratio is presently 3.6 days.

Institutional Investors Weigh In On TriSalus Life Sciences

An institutional investor recently bought a new stake in TriSalus Life Sciences stock. State Street Corp bought a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 610,963 shares of the company’s stock, valued at approximately $2,780,000.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSIW opened at $0.98 on Wednesday. TriSalus Life Sciences has a 12-month low of $0.44 and a 12-month high of $1.85. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $0.85.

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology company focused on developing and commercializing therapies and medical technologies for difficult-to-treat solid tumors, particularly liver and pancreatic cancers. The company combines interventional oncology, drug delivery and immunotherapy to address the tumor microenvironment and improve treatment delivery.

TriSalus’ technology platform includes Pressure-Enabled Drug Delivery (PEDD), a method designed to help administer therapies directly into tumors or their associated blood vessels.